Tumor cell plasticity and intrinsic immunogenicity: Implications for immunotherapy resistance in small‐cell lung cancer
Author:
Open Access
- 31 August 2021
- journal article
- editorial
- Published by Wiley in Thoracic Cancer
- Vol. 12 (19) , 2523-2525
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in CancerCancer Cell, 2019
- Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?Cancer Communications, 2019
- Molecular analysis of cell‐free DNA identifies distinct molecular features in patients with chemosensitive and chemorefractory small cell lung cancerCancer Communications, 2019
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung CancerCancer Cell, 2019
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Tumor innate immunity primed by specific interferon-stimulated endogenous retrovirusesNature Medicine, 2018
- Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 StudyJournal of Clinical Oncology, 2017
- Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?European Journal of Cancer, 2016
- Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to RomeFrontiers in Immunology, 2015
- CHARACTERIZATION OF VARIANT SUBCLASSES OF CELL-LINES DERIVED FROM SMALL CELL LUNG-CANCER HAVING DISTINCTIVE BIOCHEMICAL, MORPHOLOGICAL, AND GROWTH-PROPERTIES1985